Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.
These pioneering data were highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions Paris (France), December 8, 2021 […]
Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member Paris […]
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]
Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]
Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee […]
By invitation only For more information, visit : www.keplercheuvreux.com Download management presentation
All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]
This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]
This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]
Hybrid Conference In-Person Location – New York City Click here for more information and to register
Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership. Click here to register To set up virtual meetings with […]
This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]
This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]
Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
The management will comment the financial results and provide an update on the Company’s activities and perspectives through a video […]
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]
More information coming soon
For more information, visit the MEET2WIN Convention website To meet with us during the Convention, please contact bd@onxeo.com
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]
Watch the interview (in French)
The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]
Watch the e-poster “AsiDNA™ targets drug-tolerant persister cells responsible of resistance to PARP inhibitors”
For more information Download the presentation “AsiDNA™ and PARP inhibitors: Drug-driven synthetic lethality and beyond” Watch the video of […]
This study is supported by a grant from the European Fight Kids Cancer program[1] Paris (France), February 4, 2021 […]
Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]
This financing extends the Company’s cash horizon to the 3rd quarter of 2022 Paris (France), January 28, 2021 – […]
For more information and to register …
For more information, visit the Edison Open House Global Healthcare 2021 webpage Download the management presentation Access the interview […]
For more information, click here Download the management presentation
2020 Full-year report on the liquidity contract
Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]